Paper36005753
Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y and 2 others. Antimicrob Agents Chemother, 2022. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy. Papers, record 36005753. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36005753
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Continuous Renal Replacement Therapy | Major topic |
| Critical Illness | Major topic |
| Adult | |
| Anti-Bacterial Agents | |
| Humans | |
| Meropenem | |
| Microbial Sensitivity Tests | |
| Prospective Studies | |
| Renal Replacement Therapy |
Source PubMed
References37
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33818823 | Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis. | Br J Clin Pharmacol | 2021 | https://conductscience.org/library/papers/33818823 | PubMed |
| 2 | 26903338 | The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). | JAMA | 2016 | https://conductscience.org/library/papers/26903338 | PubMed |
| 3 | 30833427 | Considerations for Dose Selection and Clinical Pharmacokinetics/Pharmacodynamics for the Development of Antibacterial Agents. | Antimicrob Agents Chemother | 2019 | https://conductscience.org/library/papers/30833427 | PubMed |
| 4 | 33292582 | The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcome. | J Intensive Care | 2020 | https://conductscience.org/library/papers/33292582 | PubMed |
| 5 | 25737147 | Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. | J Infect Chemother | 2015 | https://conductscience.org/library/papers/25737147 | PubMed |
| 6 | 21914174 | Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. | Crit Care | 2011 | https://conductscience.org/library/papers/21914174 | PubMed |
| 7 | 10752806 | Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. | Crit Care Med | 2000 | https://conductscience.org/library/papers/10752806 | PubMed |
| 8 | 26124172 | Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/26124172 | PubMed |
| 9 | 9736573 | Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. | Antimicrob Agents Chemother | 1998 | https://conductscience.org/library/papers/9736573 | PubMed |
| 10 | 14615469 | Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. | J Clin Pharmacol | 2003 | https://conductscience.org/library/papers/14615469 | PubMed |
| 11 | 16239363 | Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. | J Clin Pharmacol | 2005 | https://conductscience.org/library/papers/16239363 | PubMed |
| 12 | 7648757 | Meropenem clinical pharmacokinetics. | Clin Pharmacokinet | 1995 | https://conductscience.org/library/papers/7648757 | PubMed |
| 13 | 30376103 | Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/30376103 | PubMed |
| 14 | 11057794 | Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. | Crit Care Med | 2000 | https://conductscience.org/library/papers/11057794 | PubMed |
| 15 | 12660337 | Acute renal failure in patients with sepsis in a surgical ICU: predictive factors, incidence, comorbidity, and outcome. | J Am Soc Nephrol | 2003 | https://conductscience.org/library/papers/12660337 | PubMed |
| 16 | 18307371 | Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. | Clin Pharmacokinet | 2008 | https://conductscience.org/library/papers/18307371 | PubMed |
| 17 | 32543786 | Data Digitizing: Accurate and Precise Data Extraction for Quantitative Systems Pharmacology and Physiologically-Based Pharmacokinetic Modeling. | CPT Pharmacometrics Syst Pharmacol | 2020 | https://conductscience.org/library/papers/32543786 | PubMed |
| 18 | 29091190 | Too much of a good thing: a retrospective study of β-lactam concentration-toxicity relationships. | J Antimicrob Chemother | 2017 | https://conductscience.org/library/papers/29091190 | PubMed |
| 19 | 25881576 | A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. | Crit Care | 2015 | https://conductscience.org/library/papers/25881576 | PubMed |
| 20 | 26598098 | Implications of Augmented Renal Clearance on Drug Dosing in Critically Ill Patients: A Focus on Antibiotics. | Pharmacotherapy | 2015 | https://conductscience.org/library/papers/26598098 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42950477 | Population pharmacokinetic model-based determination of enrofloxacin susceptibility breakpoints and dosing regimens for Salmonella in chickens. | Poult Sci | 2026 | https://conductscience.org/library/papers/42950477 | PubMed |
| 42882158 | Pharmacokinetic/Pharmacodynamic Optimization and Therapeutic Drug Monitoring of Beta-Lactam Antibiotics in Abdominal Sepsis: Current Evidence, Challenges, and Clinical Perspectives-A Narrative Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/42882158 | PubMed |
| 42781062 | Prediction of Meropenem Target Attainment in Critically Ill Patients Using Routine Clinical Data from a Single Center: A Machine Learning Approach. | Infect Drug Resist | 2026 | https://conductscience.org/library/papers/42781062 | PubMed |
| 41792368 | Development and validation of a machine learning model for individualised meropenem dosing in CRRT patients. | Sci Rep | 2026 | https://conductscience.org/library/papers/41792368 | PubMed |
| 40955911 | Precision Dosing of Meropenem in a Neonate on CARPEDIEM Dialysis: A Grand Round. | Ther Drug Monit | 2025 | https://conductscience.org/library/papers/40955911 | PubMed |
| 40884551 | Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy. | Eur J Clin Pharmacol | 2025 | https://conductscience.org/library/papers/40884551 | PubMed |
| 40421221 | Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40421221 | PubMed |
| 40265202 | Kidney replacement therapy during extracorporeal membrane oxygenation: pathophysiology, technical considerations, and outcomes. | Ren Fail | 2025 | https://conductscience.org/library/papers/40265202 | PubMed |
| 39991086 | Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function. | Drug Des Devel Ther | 2025 | https://conductscience.org/library/papers/39991086 | PubMed |
| 39200055 | Association between Extended Meropenem Regimen and Achievement of Aggressive PK/PD in Patients Receiving Continuous Renal Replacement Therapy for Septic AKI. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39200055 | PubMed |
| 38656186 | How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38656186 | PubMed |
| 38410250 | Covariates in population pharmacokinetic studies of critically ill adults receiving β-lactam antimicrobials: a systematic review and narrative synthesis. | JAC Antimicrob Resist | 2024 | https://conductscience.org/library/papers/38410250 | PubMed |
| 37887225 | Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/37887225 | PubMed |
| 37366501 | Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients. | Infect Drug Resist | 2023 | https://conductscience.org/library/papers/37366501 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36005753
GET https://conductscience.org/api/papers/v1/36005753/references?page=2